New treatment to beat severe incontinence
Scientists have developed a potential treatment for severe incontinence that means the millions of sufferers worldwide could one day throw away their incontinence pads.
University of Melbourne scientists, who developed the technique, have now licensed the intellectual property to Continence Control Systems International P/L (CCS), an Australian company created to commercialise the technology that will address a worldwide potential market of more than A$1 billion per year.
Urinary incontinence is the involuntary loss of urine from the bladder. The research team from three University departments (Anatomy, Zoology and Surgery) has found a way of creating a ring of muscle from the patients own body and transplanting it to the bladder where it acts as a replacement sphincter. One of the causes of the most common type of urinary incontinence, known as stress incontinence, is when the sphincter muscle no longer dependably keeps urine in the bladder.
The replacement sphincter is controlled by an implanted electrical stimulator that should, for the first time, give sufferers of severe stress incontinence, a reliable method of passing urine only when they want. Under terms of an exclusive supply agreement with CCS, the necessary implanted technology will be provided by Cochlear Limited.
“The only surgical solutions available until now have involved prosthetic devices that have had problems with leakage, failure and adverse tissue reactions,” says University of Melbournes Professor John Furness and one of the inventors of the treatment.
“This treatment has the potential to revolutionise the management of severe urinary incontinence which afflicts tens of thousands of people worldwide. This is a miserable condition, and if not effectively managed, can result in people entering nursing homes or institutions because they are unable to cope,” he says.
“The most common cause of a defective sphincter muscle is trauma to the area, for example as a complication of prostate surgery in men, or more frequently in women as they reach menopause, particularly if they have had children,” says Furness.
CCS will seek to raise up to $A8M in equity funds to complete the development work leading to clinical trials in 2005, which if successful, will result in a commercial product available for sale within five years.
“The number of people suffering from this condition means there is a large potential market. This research breakthrough by the University and access to Cochlears technology creates a partnership of two of Australias greatest innovators, which will accelerate the development program,” says CEO of CCS, Mr Tony Stephens.
The capital raising is being conducted by Nextec BioSciences, a Melbourne based Investment Banking Company specialising in the Biotechnology sector.
All news from this category: Health and Medicine
This subject area encompasses research and studies in the field of human medicine.
Among the wide-ranging list of topics covered here are anesthesiology, anatomy, surgery, human genetics, hygiene and environmental medicine, internal medicine, neurology, pharmacology, physiology, urology and dental medicine.
Bringing atoms to a standstill: NIST miniaturizes laser cooling
It’s cool to be small. Scientists at the National Institute of Standards and Technology (NIST) have miniaturized the optical components required to cool atoms down to a few thousandths of…
Record-breaking laser link could help us test whether Einstein was right
Scientists from the International Centre for Radio Astronomy Research (ICRAR) and The University of Western Australia (UWA) have set a world record for the most stable transmission of a laser signal through…
Adaptive optics with cascading corrective elements
A cascaded dual deformable phase plate wavefront modulator enables direct AO integration with existing microscopes–doubling the aberration correction range and greatly improving image quality. Microscopy is the workhorse of contemporary…